Sakurada H, Hiyoshi Y, Tejima T, Yanase O, Tokuyasu Y, Watanabe K, Motomiya T, Sugiura M, Hiraoka M
Department of Cardiology, Tokyo Metropolitan Hiroo General Hospital.
Kokyu To Junkan. 1990 May;38(5):471-6.
Oral flecainide treatment was given to five patients who were refractory to conventional antiarrhythmic agents. The five patients included one with atrioventricular reentrant tachycardia (AVRT), one with non-sustained ventricular tachycardia (nsVT) and three with sustained VT (sVT). Flecainide produced favorable responses in patients of AVRT, nsVT and sVT with arrhythmogenic right ventricular dysplasia (ARVD). In the case of AVRT, flecainide exhibited a preventive effect on tachycardia induced by programmed electrical stimulation (PES). In the case of nsVT, flecainide markedly reduced the number of VPC and abolished the VT on the Holter ECG. In the case of sVT with ARVD, sVT was not induced by PES after the flecainide. Long-term treatment with flecainide on these three cases produced complete prevention of tachycardias. As an adverse effect of flecainide, an aggravation of congestive heart failure was recognized in one case with cardiac sarcoidosis. PQ interval and QRS interval in all the cases were prolonged after flecainide. The results indicate that flecainide is a useful antiarrhythmic agent for tachyarrhythmias refractory to treatment with conventional drugs.
对五名对传统抗心律失常药物难治的患者给予口服氟卡尼治疗。这五名患者包括一名房室折返性心动过速（AVRT）患者、一名非持续性室性心动过速（nsVT）患者和三名持续性室性心动过速（sVT）患者。氟卡尼对AVRT、nsVT以及伴有致心律失常性右室发育不良（ARVD）的sVT患者产生了良好疗效。对于AVRT患者，氟卡尼对程序电刺激（PES）诱发的心动过速具有预防作用。对于nsVT患者，氟卡尼显著减少室性早搏（VPC）数量，并消除了动态心电图上的室性心动过速。对于伴有ARVD的sVT患者，服用氟卡尼后PES未诱发sVT。对这三例患者进行氟卡尼长期治疗可完全预防心动过速。作为氟卡尼的不良反应，一名心脏结节病患者出现充血性心力衰竭加重。所有病例服用氟卡尼后PQ间期和QRS间期均延长。结果表明，氟卡尼是一种对传统药物治疗难治的快速性心律失常有用的抗心律失常药物。
